Redux dexfenfluramine: IPIC and partner Wyeth-Ayerst began a Phase IV trial

The two-year, double-blind trial will use behavioral and neuropsychological testing to

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE